JAZZ Q3 2024 Earnings — Jazz Pharmaceuticals plc Revenue & Financial Results | Market Cap Arena

JAZZJazz Pharmaceuticals plc

$12B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1.1B+8.5% YoY

Gross Profit

$943M89.4% margin

Operating Income

$260M24.7% margin

Net Income

$215M20.4% margin

EPS (Diluted)

$3.42

QoQ Revenue Growth

+3.0%

Cash Flow

Operating Cash Flow

$399M

Free Cash Flow

$388M

Stock-Based Comp.

$60M

Balance Sheet

Total Assets

$12.3B

Total Liabilities

$8.1B

Stockholders' Equity

$4.2B

Cash & Equivalents

$2.2B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.1B	$972M	+8.5%
Gross Profit	$943M	$870M	+8.4%
Operating Income	$260M	$172M	+50.9%
Net Income	$215M	$147M	+46.5%

Revenue Segments

Xywav

$388M37%

Epidiolex/Epidyolex

$252M24%

Rylaze/Enrylaze

$99M9%

Zepzelca

$86M8%

Defitelio/Defibrotide

$66M6%

High Sodium AG Oxybate Product Royalty Revenue

$58M6%

Xyrem

$58M6%

Vyxeos

$34M3%

Other Royalty And Contract Revenues

$7M1%

Sativex

$5M0%

Other Products

$2M0%

Geographic Segments

UNITED STATES

$954M90%

Europe

$77M7%

Other Countries

$24M2%